Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Wedbush from $44.00 to $45.00. They now have an "outperform" rating on the stock.
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) had its price target raised by analysts at Piper Sandler from $48.00 to $51.00. They now have an "overweight" rating on the stock.
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
Edgewise's EDG-7500 shows benefit in two obstructive HCM trials [Yahoo! Finance]